Observational Analysis of the Associational Between Dietary Factors and Postprandial Glucose Fluctuations
NCT ID: NCT07117188
Last Updated: 2025-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
48 participants
OBSERVATIONAL
2025-08-05
2026-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diabetes and Metabolic Postprandial Responses
NCT00767208
The Influence of Glucose Flux on Fat Synthesis in a Whole Body Calorimeter
NCT02631083
Glucose and Insulin Responses to Test Foods
NCT01671878
Macronutrient Distribution and Plasma Metabolites to Model Meals Composition
NCT04928872
Acute Effects of Oral Carbohydrate and Fat Loads on Systemic Microvascular Endothelial Function in Healthy Individuals.
NCT03515460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
diabetes cohort
No interventions assigned to this group
Non-diabetic cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. diagnosed with type 2 diabetes is more than one month
2. Glycated hemoglobin (HbA1c) : 6.5%\<HbA1c\<10.5%(48 mmol/mol \< HbA1c \< 91.3 mmol/mol)
3. Requirements for the blood glucose management plan: Within one month before the start of the trial, a simple lifestyle, and/or one or more oral hypoglycemic drugs (metformin, DPP-4 inhibitors, SGLT-2 inhibitors, TZD drugs, GLP-1 receptor agonists), and/or basal insulin treatment once a day were adopted, and the regimen was required to be maintained stably within 7 days before the start of the trial and during the trial.
4. Take the test voluntarily and sign the informed consent form.
* For Non-diabetic cohort:
1. Glycated hemoglobin (HbA1c) : HbA1c\<5.7%
2. Fasting blood glucose was between 3.9 and 5.6 mmol/L, and 2-hour postprandial blood glucose was less than 7.8mmol/L
3. Take the test voluntarily and sign the informed consent form.
Exclusion Criteria
2. Epilepsy or cognitive impairment, immunosuppressive disorders, and systemic neurological diseases.
3. Required emergency or inpatient treatment due to severe hypoglycemia (blood glucose \< 3.0mmol/L with consciousness disorder), diabetic ketoacidosis, or non-ketotic hyperosmolar syndrome in the past six months.
4. Severe circulatory disorders.
5. Long-term gastrointestinal diseases (such as celiac disease, gastroparesis, etc.), or eating disorders or having undergone bariatric surgery (such as gastric bypass surgery); Has a history of severe infection within the past month; History of malignant tumors (except skin cancer); Mental illnesses such as depression; Severe liver and kidney dysfunction (renal function: estimated eGFR\<30mL/min or maintenance dialysis required;) Liver function: ALT and AST\>3 times the upper limit of the normal value or active liver disease. History of severe cardiovascular disease (NYHA cardiac function classification III-IV or BNP \>400 pg/mL).
6. Technical or language barriers: Inability to use research applications or understand text; Unable to cooperate with the use of research equipment such as continuous blood glucose monitors and accelerometers.
7. Drug use: Immunosuppressants, proton pump inhibitors, or steroid drugs have been used in the past 4 weeks or are planned to be used during the study period.
8. BMI\<16.5 kg/m².
9. Magnetic resonance imaging (MRI) examination is planned or conducted within 16 days of product use.
10. Pregnant and lactating women, and those planning to become pregnant during the study period.
11. Those whom the researchers consider unsuitable to participate in this clinical study.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United Imaging Healthcare
UNKNOWN
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20250519040454800
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.